CardioIQ Insulin Resistance Score Test

Insulin resistance is the metabolic shift that precedes almost every case of type 2 diabetes, and it accelerates heart disease even in people whose blood sugar still looks normal. The problem is that routine lab work, including fasting glucose and HbA1c (a measure of average blood sugar over three months), can stay in the normal range for years while insulin resistance quietly worsens. By the time those numbers move, the damage to blood vessels and the pancreas may already be underway.

The CardioIQ Insulin Resistance Score uses a technology called NMR (nuclear magnetic resonance) spectroscopy to analyze the sizes and quantities of fat-carrying particles in your blood. Instead of measuring insulin directly, it reads the lipoprotein signature that insulin resistance leaves behind: larger triglyceride-rich particles, smaller and denser LDL particles, and smaller HDL particles. The result is a single number that estimates where you fall on the spectrum from insulin sensitive to insulin resistant.

What This Score Actually Measures

Your body packages fats into lipoprotein particles to shuttle them through the bloodstream. When your cells respond normally to insulin, these particles tend to be a certain mix of sizes. As insulin resistance develops, the pattern shifts: your liver produces more large, triglyceride-rich particles (large VLDL), your LDL particles become smaller and more numerous, and your HDL particles shrink. The CardioIQ Insulin Resistance Score captures this shift by measuring the particle profile and converting it into a score.

This approach is closely related to a research measure called the LP-IR (Lipoprotein Insulin Resistance) score, which has been validated against gold-standard insulin sensitivity tests. A separate, conceptually related score called METS-IR (Metabolic Score for Insulin Resistance), which is calculated from standard lab values and body weight rather than NMR particle analysis, achieved an area under the curve of 0.84 in a study of over 6,200 adults, meaning it distinguished insulin-resistant from insulin-sensitive individuals with good accuracy. The LP-IR score specifically has been shown to predict future diabetes risk in large prospective studies.

Diabetes Risk

The strongest evidence for lipoprotein-based insulin resistance scores comes from diabetes prediction. In the Women's Health Study, which followed nearly 26,000 initially healthy women for up to 20 years, those with the highest LP-IR scores were substantially more likely to develop type 2 diabetes than those with the lowest scores, even after accounting for standard risk factors like BMI, fasting glucose, and HbA1c. The score improved the ability to correctly classify who would and would not develop diabetes beyond what traditional markers could do alone.

A separate study in nearly 6,000 adults from the PREVEND (Prevention of Renal and Vascular End-Stage Disease) cohort confirmed that elevated LP-IR was independently associated with incident type 2 diabetes. In a study of over 7,500 middle-aged and older adults using METS-IR (a related insulin resistance index calculated from standard lab values and body weight), higher scores were significantly associated with new-onset type 2 diabetes regardless of baseline blood pressure, suggesting insulin resistance scoring captures metabolic risk that blood pressure screening alone would miss.

Heart Disease and Stroke

Insulin resistance does not just predict diabetes. It independently raises the risk of heart attack, stroke, and cardiovascular death. A study of about 3,600 elderly adults found that those with the highest insulin resistance probability scores (above 80%) had roughly 50% greater risk of developing cardiovascular disease compared to those with lower scores. This association held after adjusting for age, sex, BMI, blood pressure, lipids, glucose, and smoking.

Studies using METS-IR (a related insulin resistance index calculated from standard lab values rather than NMR particle analysis) show a consistent pattern. A 2025 meta-analysis pooling multiple METS-IR cohort studies found that each increase in insulin resistance score was independently associated with higher incidence of composite cardiovascular disease, coronary artery disease, and stroke. In over 14,000 adults from the U.S. national health survey (NHANES), those in the highest METS-IR group had significantly greater all-cause and cardiovascular mortality than those in the lowest group, with the association being particularly strong in adults under 65. While METS-IR and the NMR-based CardioIQ score use different inputs, both estimate the same underlying condition, and the cardiovascular risk signal is consistent across methods.

If your score comes back elevated, this is a signal to look more closely at your cardiovascular risk factors. Order a full lipid panel including ApoB (apolipoprotein B, the protein on every harmful cholesterol particle) and hs-CRP (high-sensitivity C-reactive protein, a marker of vascular inflammation) to get a more complete picture of your arterial risk.

The U-Shaped Curve: Why Very Low Scores Are Not Always Reassuring

Several studies using METS-IR (a related insulin resistance index) have found that the relationship between insulin resistance scores and death is not a straight line. In patients with existing cardiovascular disease, diabetes, or kidney disease, risk was highest at both the top and bottom of the score range, forming a U shape. In one study of about 2,500 adults with cardiovascular disease, those at both extremes of the METS-IR score had higher mortality than those in the middle.

This does not mean low insulin resistance is dangerous. Rather, a very low score in someone who is already sick may reflect severe weight loss, malnutrition, or advanced illness rather than metabolic health. The takeaway: in otherwise healthy people, a lower score is generally better. But if you have an existing condition and your score drops unexpectedly low, it is worth discussing with a physician to understand the context.

How to Read Your Score

The CardioIQ Insulin Resistance Score is reported on a scale that typically ranges from about 0 to 100, with higher scores indicating greater insulin resistance. Because this is a proprietary score without universally standardized clinical cutpoints endorsed by major guidelines, the most useful way to interpret it is relative: where you fall within your lab's reported range, and how your number changes over time.

The LP-IR score, the research equivalent most closely aligned with this test, has been studied with cutpoints in some validation cohorts. In the PREVEND study, higher LP-IR quartiles were associated with progressively greater diabetes risk. In the Women's Health Study, the top LP-IR quintile carried significantly higher diabetes incidence than the bottom. Your lab report will typically flag your result as low, moderate, or high risk based on the manufacturer's thresholds.

Because this score is derived from NMR lipoprotein analysis, your results are best compared within the same lab over time. Different NMR platforms can produce slightly different values, so switching labs between tests makes trending less reliable.

When Results Can Be Misleading

The most important confounder for any insulin resistance measure is biological variability. A study of 90 healthy adults found that HOMA-IR (a related insulin-based index) varied by about 27% from week to week in the same person, even under controlled fasting conditions. While the lipoprotein-based score may be somewhat more stable than direct insulin measurement because it reflects a structural pattern rather than a single hormone level, a single reading still carries meaningful uncertainty.

In women of reproductive age, insulin resistance markers fluctuate across the menstrual cycle, with the timing of peaks differing by age group. A study of over 1,200 women found that fasting insulin and related indices showed significant rhythmic variation, meaning that the timing of your blood draw within your cycle can shift your result. Shift workers also tend to have higher insulin resistance scores independent of diet and exercise habits, likely due to circadian disruption (the misalignment between your internal body clock and your sleep-wake schedule).

Acute illness, recent surgery, or severe physical stress can temporarily distort lipid and glucose metabolism, pushing your score higher than your baseline. If you have been sick or had a major physical stressor in the past two to three weeks, consider waiting before testing. A fasting blood draw (at least 10 to 12 hours without food) is essential, since a recent meal directly changes triglyceride-rich particle levels and would inflate the score.

Tracking Your Trend

Given the natural variability in insulin resistance measurements, a single score is best treated as a starting point, not a verdict. Get a baseline reading, then retest in three to six months if you are making dietary, exercise, or medication changes. After that, annual testing gives you a reliable trajectory. The direction your number is heading matters more than any single value.

One large cohort study of over 47,000 adults found that the cumulative burden of insulin resistance over time, measured using a related index called TyG (calculated from fasting glucose and triglycerides, not NMR particle analysis), was what most strongly predicted future cardiovascular events. People whose scores drifted upward over years had significantly higher risk than those who maintained stable, lower levels. Although TyG and the NMR-based CardioIQ score use different inputs, the principle holds: catching an upward trend early gives you the chance to intervene before your risk escalates.

If your score is in the high range on two separate occasions at least a month apart, pair it with fasting insulin, fasting glucose, HbA1c, and a full lipid panel to understand the full metabolic picture. A high insulin resistance score alongside normal glucose and HbA1c is actually the most actionable scenario: it means your pancreas is still compensating, but the underlying metabolic stress is real and modifiable.

What to Do With an Elevated Result

An elevated score should prompt a broader metabolic workup. Order fasting insulin and glucose (to calculate HOMA-IR, a complementary insulin resistance measure), HbA1c, a standard lipid panel, ApoB, and hs-CRP. If your waist circumference is above 40 inches for men or 35 inches for women, or if you have a family history of type 2 diabetes, these companion tests become especially informative.

For persistently elevated scores with evidence of metabolic syndrome (high triglycerides, low HDL, elevated waist circumference, borderline glucose, or elevated blood pressure), consider consulting an endocrinologist or a physician experienced in cardiometabolic risk. The combination of a high insulin resistance score with elevated ApoB is a particularly high-risk pattern that may warrant medication discussions even if individual markers are only mildly abnormal.

The good news: insulin resistance is one of the most modifiable metabolic risk factors. Exercise, dietary changes, weight loss, and certain medications can all shift the underlying biology this score tracks, making it a useful gauge for whether your interventions are actually working.